Scioderm is a privately held, clinical-stage pharmaceutical company focused on developing topical products to address critical medical needs in the treatment of chronic skin diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/26/13 | $16,000,000 | Series A |
Morgenthaler | undisclosed |
| 12/22/14 | $20,000,000 | Series B |
Redmile Group Technology Partners | undisclosed |
